We calculated weighted hours of formaldehyde exposure from each job as the product of job duration (assuming 50 working weeks per year) and weekly working hours weighted by the three-level scale (weights of 0.5, 1, and 2 were given to levels 0 1, 1, and 2, respectively); these were then summed over all jobs to derive weighted lifetime hours of exposure.
Additionally, the ratios of evening (12 24-hour 12 24-hourg (0–12-hour) weightod morningV1 values were approximately 1.0 12-hour QD doses indicating that the 24-hour duration of effect is an intrinsic property of UMEC rather than being of a dose-related nature.
Remedication data were pooled from four trials [37, 42, unpublished studies] to give the percentage remedicating by 12 hours, weighted by the number of patients.
The ratios of evening (12 24 hours) to morning (0 12 hours) weighted mean FEV1 values were approximately 1.0 for all UMEC QD and BID doses; whereas the ratio for tiotropium was approximately 0.8 (Table 6).
NTISS [ 28] is a score of neonatal therapeutic intensity calculated from a checklist of 63 NICU therapies used in a 24 hour period, weighted according to invasiveness and cost.
*Relative to 0 12-hour weighted mean FEV1.
Dose ordering was observed across QD dose regimens with UMEC 125 μg QD showing the greatest improvements in 0 24-hour weighted mean FEV1.
Improvements in the adjusted mean changes from baseline for UMEC QD doses in 12 24-hour 12 24-hourean FEV1 over placebo weightederally simeanr or greater than those observed FEV10–12-hoverweighted mean FEV1, indicating sustained duration of action (Table 5).
Statistically significant increases in the adjusted mean changes from baseline in trough and 0 24-hour weighted mean FVC over placebo on Day 7 were demonstrated for all UMEC QD and BID doses.
However, trough FEV1 does not convey the full picture of bronchodilation offered to patients, and thus the 24-hour weighted mean and 24-hour serial FEV1 profiles were also evaluated.
Statistically significant improvements in the adjusted mean changes from baseline in 0 24-hour weighted mean FEV1 over placebo on Day 7 were observed for all UMEC QD and BID doses and for tiotropium (Table 3).
